

Dr. Andrea Calcagno



Current position Since October 2020 Associate Professor of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.

Education Infectious Diseases Specialist since December 2007; graduated with honours at the University of Torino with a dissertation on the pharmacogenetics of nevirapine entitled "Effects of Cytochrome P450 2B6 Single Nucleotide Polymorphisms on the pharmacokinetic profile of nevirapine in a heterogenous cohort of HIV-infected patients".

Diploma in Tropical Medicine & Hygiene (DTM&H) at the Mahidol University, Bangkok, Thailand during 2006.

Graduated with honours in Medicine and Surgery at the University of Torino, Torino, Italy with a dissertation on antibiotic resistance in Intensive Care Units.

Admitted to the college of Physicians of Torino on the 19th December 2003.

Clinical Experience October 2012 - September 2020 Temporary Assistant Professor in Infectious Diseases ("RTD-B" since October 2017), Department of Medical Sciences, University of Turin.

Temporary Research Fellow at the University of Torino, Department of Infectious Diseases (March 2008- March 2012): shifts as Infectious Diseases Consultant and work as Clinical Researcher. Receiving a grant from the University of Torino for a research project entitled "Pharmacokinetics and Pharmacogenetics of raltegravir".

Six months (October 2006 – April 2007) and then one month (February 2009) in a rural hospital in Burundi as responsible of Paediatric and Malnourished children ward (50 beds) and HIV clinic. During this period two studies were conducted (on malaria and HIV).

Since October 2003 working in the HIV Clinic of the "Ospedale Amedeo di Savoia" in Torino mainly researching pharmacokinetics and pharmacodynamics of antiretroviral drugs. Participated in the conduction of phase II and phase III Clinical Trials.

During August 2003 one month attendance in the Internal Medicine ward of the University Hospital in Khartoum (Sudan).

2001/2 medical course attended at the University of Cordoba, Cordoba, Spain.

Spoken Languages Good knowledge of English and Spanish, basic knowledge of French. Italian as mother tongue.

Teaching Experience From the academic year 2013/2014 responsible of the Infectious Diseases course at the Nursing School and from the academic year 2017/2018 co-responsible of the Infectious Disease course at the School of Medicine and Surgery, University of Torino. Since 2007 participates in the preparation and conduction of lectures during the Infectious Diseases Course at the University of Torino (both to Medical Students and Nursing school students). Since 2012 teaching in the post-graduate school in Infectious Diseases at the University of Torino.

2007-present lecturer at the “Residential Course on Clinical Pharmacology of Antiretrovirals” organized by the Unit of Infectious Diseases, Department of Medical Sciences, University of Torino.

Associate Professor Qualification National Scientific Qualification (art.16 of the law 30 December 2010, n.240) for Associate Professor obtained on August 3rd 2017 (and valid until August 3rd, 2023).

Ordinary Professor Qualification National Scientific Qualification (art.16 of the law 30 December 2010, n.240) for Ordinary Professor obtained on October 31st 2018 (and valid until October 30th, 2024).

Appointments 2015-2019 Member of the Governing Council of the Italian Society of Infectious Diseases and Tropical Medicine (SIMIT).

Editorial Board Since 2018, Academic Editor of “PlosOne”.

Since 2017, Coordinator of the Study group on Mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine (SIMIT).

Since 2017 in the Scientific Committee of “IRENE” (Italian Registry of Pulmonary non tubecular Mycobacteria).

Since 2015 member of the GEPPPO (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group and from 2017 in the Scientific Committee of the cohort.

Since 2015, Vice Editor of “Infectious Diseases and Tropical Medicine”.

Since 2015, in the Scientific Committee of the ICONA foundation (Italian Cohort Naïve Antiretrovirals).

Since 2013, Associate Editor of “BMC Infectious Diseases” Journal.

Conference Organization

Since 2018, Member of the Organizing Committee of the International "Antivirals PK Workshop".

Member of the Scientific Committee of the 12th Italian Conference on AIDS and Retroviruses, 2020, 5-7 May, Riccione, Italy.

Member of the Scientific Committee of the 11th Italian Conference on AIDS and Retroviruses, 2019, 5-7 June, Milan, Italy.

Member of the Scientific Committee of the 10th Italian Conference on AIDS and Retroviruses, 2018, 22-24 May, Rome, Italy.

Member of the Scientific Committee of the 9th Italian Conference on AIDS and Retroviruses, 2017, 12-14 June, Siena, Italy.

Member of the Scientific Committee of the 8th Italian Conference on AIDS and Retroviruses, 2016, 6-8 June, Milano, Italy.

Member of the Scientific Committee of the 5th Italian Conference on AIDS and Retroviruses, 2013, 12-14 May, Torino, Italy.

Guidelines

Since 2012 in the HIV/AIDS expert Panel writing the Italian Guidelines on the use of antiretroviral drugs and on the management of HIV-positive patients.

International Collaborations

Since 2014, Collaboration with the Infectious Disease Institute, Makerere University, Kampala, Uganda. Capacity building for the creation of a Laboratory of Pharmacogenetics in Uganda and conduction of phase IV studies. He won two Erasmus+ projects (in collaboration with the Department of Social Sciences) for the years 2020-2022 and 2021-2023 for promoting the exchange between the University of Torino and the Makerere University.

Awards

- Winner of the "ICAR CROI Award 2012" for young Italian researchers for the project entitled "Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting" (Calcagno A et al. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 Marzo 2012, P603).
- Winner of the "ICAR CROI Award 2013" for young Italian researchers for the project entitled "Cerebrospinal Fluid Viral and Neurodegenerative Markers in HIV-positive Very Late-presenters." Calcagno A et al. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 Marzo 2013, Atlanta, GE, USA. P438).
- Winner of the "ICAR CROI Award 2014" for young Italian researchers for the project entitled "ABCC4 3348 T>C SNP Affects Tenofovir Urinary Output in HIV-Positive Patients". (Calcagno A, et al. 21st Conference on Retroviruses and Opportunistic Infections, March 3-6 2014, Boston, MA, USA. P 503).

- Winner of the "ICAR CROI Award 2015" for young Italian researchers for the project entitled "Neurocognitive Screening Tests Are Associated with Cardiovascular Risk and VACS scores" (Calcagno A, et al. 22nd Conference on Retroviruses and Opportunistic Infections, february 23-26, 2015, Seattle, WA, USA. P487).
- Winner of the "ICAR CROI Award 2016" for young Italian researchers for the project entitled "Predicting Drug Discontinuation in TDF-Tolerant Patients: A Prospective PK/PG Study" (Calcagno A, et al. 23rd Conference on Retroviruses and Opportunistic Infections. Boston, MA, US. February 22-25, 2016. P426).
- Winner of the special jury "ICAR CROI Award 2017" for young Italian researchers for the project entitled "Discordant HIV RNA in Olfactory Mucosa of HIV-positive Patients" (Calcagno A, et al. 24th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017, Seattle, WA, USA. P379).

Fund Raising

- "Ricerca Finalizzata 2013": 225.246 € for the network projects NET-2013-02355333-4 "Plasma, intracellular and tissue concentrations reached by a multi-target antiretroviral treatment during the treatment of patients with primary HIV infection: a pharmacokinetic/pharmacodynamic study".
- BMS grant support 2014: 20000 € for the project "Intracellular penetration of antiretrovirals into astrocytes: an in vitro study".
- Gilead Fellowship 2014: 15000 € for the project "Antiretroviral toxicity on astrocytes: an *in vitro* and *in vivo* study".
- Gilead Fellowship 2012: 25000 € for the project "Determinants of proximal tubular dysfunction in HIV-positive patients: a cross-sectional analysis in patients above 50 years of age"

Orcid ID 0000-0003-2534-8815

Publications

1. Trentalange A, Borgogno E, Motta I, Antonucci M, Pirriatore V, Costa C, Rossi G, Barco A, De Nicolò A, Piccioni P, D'Avolio A, Bonora S, Perri GD, Calcagno A. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses? **Int J Antimicrob Agents**. 2021 Feb 1:106297.c Epub ahead of print.
2. Trunfio M, Salvador E, Gaviraghi A, Audagnotto S, Marinaro L, Motta I, Casciaro R, Ghisetti V, Fava C, Bonora S, Di Perri G, Calcagno A; e-COVID Study Group. Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. **Antivir Ther**. 2021 Jan 18. Epub ahead of print.
3. De Nicolò A, Ianniello A, Ferrara M, Avataneo V, Cusato J, Antonucci M, De Vivo E, Waitt C, Calcagno A, Trentalange A, Muccioli G, Bonora S, Di Perri G, D'Avolio A. Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. **Pharmaceuticals (Basel)**. 2020 Dec 25;14(1):12.
4. Calcagno A, Dal Conte I, Cattaneo D, Testi R, Mistrangelo M, Gervasoni C, de Nicolò A, Bonora S, D'Avolio A, Di Perri G. Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal

- Disorders. **Antimicrob Agents Chemother.** **2020** Oct 26:AAC.01902-20. Epub ahead of print.
5. Maggiolo F, Bandera A, Bonora S, Borderi M, Calcagno A, Cattelan A, Cingolani A, Gianotti N, Lichtner M, Lo Caputo S, Madeddu G, Maggi P, Marchetti GC, Maserati R, Nozza S, Rusconi S, Zazzi M, Di Biagio A. Enhancing care for people living with HIV: current and future monitoring approaches. **Expert Rev Anti Infect Ther.** **2020** Oct 15:1-14. Epub ahead of print.
 6. Trunfio M, Salvador E, Cabodi D, Marinaro L, Alcantarini C, Gaviraghi A, Trentalange A, Lipani F, Sciascia S, Roccatello D, Bonora S, Di Perri G, Calcagno A; e-COVID Study group. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. **Thromb Res.** **2020** Oct 8;196:432-434. Impact Factor 2.869.
 7. Calcagno A, Ghisetti V, Emanuele T, Trunfio M, Faraoni S, Boggione L, Burdino E, Audagnotto S, Lipani F, Nigra M, D'Avolio A, Bonora S, Di Perri G. Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. **Emerg Infect Dis.** **2020** Oct 6;27(1). Impact Factor 6.259.
 8. Calcagno A, Ghisetti V, Burdino E, Trunfio M, Alice T, Boggione L, Bonora S, Di Perri G. Coinfection with other respiratory pathogens in COVID-19 patients. **Clin Microbiol Infect.** **2020** Aug 19:S1198-743X(20)30494-8. Impact Factor 7.117.
 9. De Benedetto I, Trunfio M, Guastamacchia G, Bonora S, Calcagno A. A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs. **J Neurovirol.** **2020** Jul 31. [Epub ahead of print] Impact Factor: 2.763.
 10. Calcagno A, Moltò J, Borghetti A, Gervasoni C, Milesi M, Valle M, Avataneo V, Alcantarini C, Pla-Junca F, Trunfio M, D'Avolio A, Di Giambenedetto S, Cattaneo D, Di Perri G, Bonora S. Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. **Clin Pharmacokinet.** **2020** Aug 1. [Epub ahead of print] Impact Factor: 4.604.
 11. Trunfio M, Rugge W, Mighetto L, Vai D, Atzori C, Nigra M, Domini S, Borgogno E, Guastamacchia G, Bonora S, Di Perri G, Calcagno A. Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. **AIDS.** **2020** Jul 21. [Epub ahead of print] Impact Factor: 4.511.
 12. Taramasso L, Fabbiani M, Nozza S, De Benedetto I, Bruzzesi E, Mastrangelo A, Pinnetti C, Calcagno A, Ferrara M, Bozzi G, FocV† E, Quiros-Roldan E, Ripamonti D, Campus M, Celesia BM, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, d'Ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Muscatello A, Gori A, Antinori A, Tambussi G, Bandera A; INACTION study group. Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. **HIV Med.** **2020**;21(8):523-535. Impact Factor: 3.556.
 13. Dravid AN, Gawali R, Betha TP, Sharma AK, Medisetty M, Natrajan K, Kulkarni MM, Saraf CK, Mahajan US, Kore SD, Rathod NM, Mahajan US, Letendre SL, Wadia RS, Calcagno A. Two treatment strategies for

- management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India. **Medicine (Baltimore)**. 2020;99(24):e20516. Impact Factor: 1.552.
14. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, Bonora S, **Calcagno A**, Cecchi I, Cinnirella G, Converso M, Cozzi M, Crosasso P, De Iaco F, Di Perri G, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, Rossi D. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. **Clin Exp Rheumatol**. 2020 May-Jun;38(3):529-532. Impact Factor: 3.238
 15. Muscatello A, Nozza S, Fabbiani M, De Benedetto I, Ripa M, Dell'acqua R, Antinori A, Pinnetti C, **Calcagno A**, Ferrara M, Focà E, Quiros-Roldan E, Ripamonti D, Campus M, Maurizio Celesia B, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, D'ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Gori A, Tambussi G, Bandera A; Inaction Study Group. Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study. **Pathog Immun**. 2020 Feb 24;5(1):8-33. Impact Factor 3.020.
 16. Mornese Pinna S, Trunfio M, Imperiale D, **Calcagno A**. JC virus DNA in cerebrospinal fluid: insight into clinical significance. **Diagn Microbiol Infect Dis**. 2020 Jun;97(2):115017. Impact factor: 2.314.
 17. Lupia T, Milia MG, Atzori C, Gianella S, Audagnotto S, Imperiale D, Mighetto L, Pirriatore V, Gregori G, Lipani F, Ghisetti V, Bonora S, Di Perri G, **Calcagno A**. Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation. **AIDS**. 2020 Mar 1;34(3):373-380. Impact factor: 4.499
 18. Joseph SB, Trunfio M, Kincer LP, **Calcagno A**, Price RW. What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system? **AIDS**. 2019 Dec 1;33 Suppl 2:S171-S179. Impact factor: 4.499
 19. Lwanga I, Nabaggala MS, Kiragga A, **Calcagno A**, Guaraldi G, Lamorde M, Castelnuovo B. Implementing routine physical function screening among elderly HIV-positive patients in Uganda. **AIDS Care**. 2019 Dec 17:1-4. Impact factor: 2.105
 20. Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, **Calcagno A**, Girardi E. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. **Int J Infect Dis**. 2020 Mar;92:62-68. Impact factor: 3.538
 21. Lupia T, Scabini S, Stroffolini G, **Calcagno A**. I have got you under my skin. **Infection**. 2020 Apr;48(2):315-316. Impact factor: 2.927
 22. Montrucchio C, De Nicolò A, D'Ettoire G, D'Ascenzo F, Lazzaro A, Tettoni M, D'Avolio A, Bonora S, Celani L, Di Perri G, **Calcagno A**. Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the

- Effect of Probiotic Supplementation. **Int J Antimicrob Agents**. 2020 Jan 25:105908. Impact factor: 4.615
23. Costa C, Scabini S, Kaimal A, Kasozi W, Cusato J, Kafufu B, Borderi M, Mwaka E, Di Perri G, Lamorde M, **Calcagno A**, Castelnovo B. Calcaneal quantitative ultrasound and urine retinol binding protein in HIV-positive antiretroviral-treated patients in Uganda: a pilot study. **J Infect Dis**. 2020 Feb 28. [Epub ahead of print] Impact factor: 5.045
 24. **Calcagno A**, Cusato J, Ferrara M, De Nicolò A, Lazzaro A, Manca A, D'Avolio A, Di Perri G, Bonora S. Antiretroviral concentrations in the presence and absence of valproic acid. **J Antimicrob Chemother**. 2020 Mar 25. [Epub ahead of print] Impact factor: 5.113
 25. Cusato J, **Calcagno A**, Marinaro L, Avataneo V, D'Avolio A, Di Perri G, Bonora S. Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. **Pharmacogenomics J**. 2019 [Epub ahead of print] Impact factor: 3.503.
 26. Focà E, Magro P, Guaraldi G, Riva A, Cattelan AM, De Socio GV, Costa C, Piconi S, Celesia BM, Nozza S, Orofino G, Castagna A, Di Perri G, Castelli F, Calcagno A; GEPP0 (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group. Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPP0" Cohort. **PLoS One**. 2019 Oct 17;14(10):e0222225. Impact factor: 2.776.
 27. Trunfio M, Manini C, Trentalange A, Boghi A, Audagnotto S, Imperiale D, Taraglio S, Bonora S, Di Perri G, **Calcagno A**. The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes. **J Neurovirol**. 2019 Jun 18. [Epub ahead of print] Impact factor: 2.302.
 28. Di Stefano A, Alcantarini C, Atzori C, Lipani F, Imperiale D, Burdino E, Audagnotto S, Mighetto L, Milia MG, Di Perri G, **Calcagno A**. Cerebrospinal fluid biomarkers in patients with central nervous system infections: a retrospective study. **CNS Spectr**. 2019 May 27:1-7. [Epub ahead of print] Impact factor: 3.940.
 29. Armenia D, Di Carlo D, Cozzi-Lepri A, **Calcagno A**, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. **Antivir Ther**. 2019 Apr 12. [Epub ahead of print] Impact factor: 2.140.
 30. Cusato J, **Calcagno A**, De Nicolò A, Mogyorosi K, D'Avolio A, Di Perri G, Bonora S. Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. **Diagn Microbiol Infect Dis**. 2019 Jun; 94(2):202-204. Impact factor: 2.314.
 31. Sekaggya-Wiltshire C, Chirehwa M, Musaaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, **Calcagno A**, Fehr JS, Kambugu A, Castelnovo B, Lamorde M, Denti P. Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines? **Antimicrob Agents Chemother**. 2019 May 24;63(6). Impact factor: 4.715.

32. Ssebambulidde K, Segawa I, Laker E, Lamorde M, Castelnuovo B, Nakasujja N, Calcagno A. Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda. **Oxf Med Case Reports**. 2019. *Not Impacted*.
33. Calcagno A, Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, Castelnuovo B, Fehr J, Di Perri G, Lamorde M. The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Co-infected Patients in Uganda in the SOUTH Study. **Clin Pharmacol Ther**. 2019. *Impact Factor 2017: 6.544*.
34. Pinzone MR, Ceccarelli M, Venanzi Rullo E, Maresca M, Bruno R, Condorelli F, Di Rosa M, Madeddu G, Focà E, Calcagno A, Celesia BM, Cacopardo B, Nunnari G, Pellicanò GF. Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease. **Biomed Rep**. 2019. *Not Impacted*.
35. Peyracchia M, Verardi R, Rubin SR, Abu-Assi E, Montrucchio C, Perl L, Grossomarra W, Calcagno A, Omedè P, Montefusco A, Bonora S, Moretti C, D'Amico M, Mauro R, D'Ascenzo F. In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis. **J Cardiovasc Med (Hagerstown)**. 2019. *Impact Factor 2017: 1.67*.
36. Mondì A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Iona Foundation Study Group. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Iona cohort. **J Int AIDS Soc**. 2019;22(1):e25227. *Impact Factor 2017: 5.131*.
37. Lupia T, Costa C, Forni N, Calcagno A. A "Tinea" immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment. **G Ital Dermatol Venereol**. 2019. *Impact Factor 2017: 1.327*.
38. Bertero L, Joseph SB, Trunfio M, Alice T, CATERA S, Imperiale D, Cassoni P, Kincer LP, Pirriatore V, Ghisetti V, Amasio E, Zanusso G, Bonora S, Di Perri G, Calcagno A. HIV-1 detection in the olfactory mucosa of HIV-1 infected participants. **AIDS**. 2019. *Impact Factor 2017: 4.914*.
39. Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, D'Avolio A, Ciccarelli N, La Monica S, Colafigli M, Delle Donne V, De Marco R, Tamburrini E, Visconti E, Di Perri G, De Luca A, Bonora S, Di Giambenedetto S. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. **J Antimicrob Chemother**. 2018. *Impact Factor 2017: 5.217*.
40. Trunfio M, Pinnetti C, Focà E, Bai F, Maffongelli G, Celani L, Cinque P, Celotti A, Andreoni M, Monforte AD, D'Ettoire G, Antinori A, Calcagno A. Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? **AIDS**. 2018. *Impact Factor 2017: 4.914*.
41. Di Perri G, Calcagno A, Trentalange A, Bonora S. The clinical pharmacology of integrase inhibitors. **Expert Rev Clin Pharmacol**. 2018. *Impact Factor 2017: 2.758*.

42. Calcagno A, Fiumanò M, Zugna D, Cusato J, Montrucchio C, Marinaro L, Trentini L, Ferrara M, D'Avolio A, Pizzi C, Di Perri G, Bonora S. Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization? **Pharmacogenomics J.** **2019**;19(1):65-71. *Impact Factor 2017: 3.812.*
43. von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. **J Antimicrob Chemother.** **2019**;74(1):135-138. *Impact Factor 2017: 5.217.*
44. Trentalange A, Prochet A, Imperiale D, Cusato J, Tettoni M, Nunnari G, Barco A, Bonora S, Di Perri G, Calcagno A. Cerebral white matter Hyperintensities in HIV-positive patients. **Brain Imaging Behav.** **2018.** *Impact Factor 2017: 3.719.*
45. Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Previdi G, Blasi F; IRENE Network. The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. **Multidiscip Respir Med.** **2018** Aug 9;13(Suppl 1):33. doi: 10.1186/s40248-018-0141-8. eCollection 2018. *Not Impacted.*
46. Merlini E, Iannuzzi F, Calcagno A, Bai F, Trunfio M, d'Arminio Monforte A, Bonora S, Marchetti G. Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). **J Neurovirol.** **2018** Jul 9. doi: 10.1007/s13365-018-0661-1. [Epub ahead of print] *Impact Factor 2016: 3.206.*
47. Scabini S, Trunfio M, Pirriatore V, Imperiale D, Audagnotto S, Bertucci R, Ghisetti V, Cinnirella G, Cistaro A, Perna M, Calcagno A, Di Perri G. Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy. **Infez Med.** **2018** Jun 1;26(2):160-163. *Not Impacted.*
48. Allegra S, Cardellino CS, Fatiguso G, Cusato J, De Nicolò A, Avataneo V, Bonora S, D'Avolio A, Di Perri G, Calcagno A. Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. **J Clin Pharmacol.** **2018** Jun 6. doi: 10.1002/jcph.1266. [Epub ahead of print] *Impact factor 2017: 2.881.*
49. Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, Calcagno A. Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. **HIV Med.** **2018** Jun 4. doi: 10.1111/hiv.12624. [Epub ahead of print] *Impact factor 2017: 2.932.*
50. Peyracchia M, De Lio G, Montrucchio C, Omedè P, d'Ettore G, Calcagno A, Vullo V, Cerrato E, Pennacchi M, Sardella G, Manga P, GrossoMarra W, Vullo F, Fedele F, Biondi-Zoccai G, Moretti C, Vachiat A, Bonora S, Rinaldi M,

- Mancone M, D'Ascenzo F. Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study. **Atherosclerosis**. **2018** Jul;274:218-226. doi: 10.1016/j.atherosclerosis.2018.05.001. Epub 2018 May 5. Impact factor 2017: 4.467.
51. Trunfio M, Vai D, Montrucchio C, Alcantarini C, Livelli A, Tettoni MC, Orofino G, Audagnotto S, Imperiale D, Bonora S, Di Perri G, Calcagno A. Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. **HIV Med**. **2018** May 15. doi: 10.1111/hiv.12622. [Epub ahead of print] Impact factor 2017: 2.932.
 52. Focà E, Calcagno A, Bonito A, Cusato J, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Castelnuovo F, Di Perri G, Castelli F, Bonora S. Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. **Antimicrob Agents Chemother**. **2018** Jun 26;62(7). pii: e00309-18. doi: 10.1128/AAC.00309-18. Print 2018 Jul. Impact factor 2017: 4.255.
 53. Guaraldi G, Malagoli A, Calcagno A, Mussi C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Riva A, Focà E, Nozza S, Di Perri G. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years. **BMC Geriatr**. **2018** Apr 20;18(1):99. doi: 10.1186/s12877-018-0789-0. Impact factor 2017: 2.866.
 54. Calcagno A, Pinnetti C, De Nicolò A, Scarvaglieri E, Gisslen M, Tempestilli M, D'Avolio A, Fedele V, Di Perri G, Antinori A, Bonora S. Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. **Br J Clin Pharmacol**. **2018** Feb 14. doi: 10.1111/bcp.13552. [Epub ahead of print] Impact factor 2016: 3.493.
 55. Bigliano P, Calcagno A, Lucchini A, Audagnotto S, Montrucchio C, Marinaro L, Alcantarini C, Ghisetti V, Di Perri G, Bonora S. The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. **Antivir Ther**. **2018** Jan 26. doi: 10.3851/IMP3221. [Epub ahead of print] Impact factor 2016: 2.594.
 56. Calcagno A, Barco A, Trunfio M, Bonora S. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose. **Curr HIV/AIDS Rep**. **2018** [Epub ahead of print] Impact factor 2016: 4.038.
 57. Palazzo A, Trunfio M, Pirriatore V, Milesi M, De Nicolò A, Alcantarini C, D'Avolio A, Bonora S, Di Perri G, Calcagno A. Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. **J Antimicrob Chemother**. **2017**. [Epub ahead of print] Impact factor 2016: 5.071.
 58. Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, Calcagno A. Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. **J Neurovirol**. **2017** [Epub ahead of print] Impact Factor 2016: 3.206.
 59. Motta I, Calcagno A, Bonora S. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? **Expert Opin Drug Metab Toxicol**. **2018**;14(1):59-82. Impact Factor 2016: 3.027.

60. Cusato J, Allegra S, Nicolò A, Calcagno A, D'Avolio A. Precision medicine for HIV: where are we? **Pharmacogenomics**. **2018** Jan;19(2):145-165. Impact factor 2016: 2.350.
61. Motta I, Trunfio M, Calcagno A, Pirriatore V, Scabini S, Palazzo A, Audagnotto S, Fatiguso G, Liberini V, Bellò M, D'Avolio A, Di Perri G, Bonora S. Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infections. **J Antimicrob Chemother**. **2017** [Epub ahead of print] Impact factor 2016: 5.071.
62. Focà E, Calcagno A, Bonito A, Simiele M, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Casari S, Di Perri G, Castelli F, Bonora S. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. **J Antimicrob Chemother**. **2017**;72(11):3163-3166. Impact factor 2016: 5.071.
63. Calcagno A, Piconi S, Focà E, Nozza S, Carli F, Montrucchio C, Cattelan AM, Orofino G, Celesia BM, Morena V, De Socio GV, Guaraldi G; GEPPPO (GERiatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group. Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-infected Patient. **J Acquir Immune Defic Syndr**. **2017** [Epub ahead of print]. Impact factor 2016: 3.935.
64. Mornese Pinna S, Scarvaglieri E, Milia MG, Imperiale D, Ghisetti V, Audagnotto S, Prochet A, Lipani F, Bonora S, Di Perri G, Calcagno A. Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? **J Neurovirol**. **2017** [Epub ahead of print] Impact factor 2016: 3.206.
65. Nozza S, Malagoli A, Maia L, Calcagno A, Focà E, De Socio G, Piconi S, Orofino G, Cattelan AM, Celesia BM, Gervasi E, Guaraldi G; GEPPPO Study Group. Antiretroviral therapy in geriatric HIV patients: the GEPPPO cohort study. **J Antimicrob Chemother**. **2017** [Epub ahead of print] Impact factor 2016: 5.071;
66. Allegra S, Fatiguso G, Calcagno A, Baietto L, Motta I, Favata F, Cusato J, Bonora S, Di Perri G, D'Avolio A. Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. **Pharmacogenomics**. **2017**;18(9):865-880. [Epub ahead of print]. Impact factor 2016: 2.350;
67. Calcagno A, Lucchini A, Caracciolo D, Balbiano R, Bracchi M, Sordella F, Gregori G, Lipani F, Audagnotto S, Chiriotto M, Cavaglià G, Ghisetti V, Di Perri G, Bonora S. High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders. **Curr HIV Res**. **2017** [Epub ahead of print].]. Impact factor 2016: 1.612;
68. Antinori A, Di Biagio A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. **New Microbiol**. **2017**;40(2):86-98. Impact factor 2016 1.720.
69. Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤ 50 cp/mL. **Infection**. **2017** [Epub ahead of print]. Impact factor 2016: 2.468;

70. Calcagno A, Pagani N, Ariaudo A, Arduino G, Carcieri C, D'Avolio A, Marinaro L, Tettoni MC, Trentini L, Di Perri G, Bonora S. Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. **J Antimicrob Chemother.** **2017.** [Epub ahead of print]. Impact factor 2016: 5.071.
71. Biagini R, Montrucchio C, Calcagno A, Trentini L, Tettoni MC, Alcantarini C, Barco A, Trentalange A, Milesi M, Ferrara M, Bertucci R, Di Perri G, Bonora S. Geriatrics in HIV infection: multimorbidity, polypharmacy and primary prevention in patients above 65 years). **Journal of HIV and Ageing.** **2017**;1:19-25. Not Impacted
72. Motta I, Alice T, Romito A, Ferrara M, Ecclesia S, Imperiale D, Ghisetti V, Di Perri G, Bonora S, Calcagno A. Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia. **Antivir Ther.** **2017** [Epub ahead of print]. Impact factor 2015: 2.910;
73. Motta I, Calcagno A, Baietto L, Bigliano P, Costa C, Baruffi K, Fatiguso G, D'Avolio A, Di Perri G, Bonora S. Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. **Br J Clin Pharmacol.** **2017.** [Epub ahead of print] Impact factor 2015: 3.830;
74. Montrucchio C., Biagini R., Alcantarini C., Calcagno A., Barco A., Ferrara M., Milesi M., Costa C., Trentalange A., Trunfio M., Tettoni M. C., Grosso Marra W., D'Ascenzo F., Ballocca F., Lonni E., Gili S., Vai D., Imperiale D., Gaita F., Bonora S., Di Perri G. Cardiovascular risk and neurocognitive deficits in HIV-positive individuals. **Infectious Diseases & Tropical Medicine** **2017**; 3 (1): e370. Not Impacted.
75. Calcagno A, Di Perri G, Bonora S. Treating HIV Infection in the Central Nervous System. **Drugs.** **2017** [Epub ahead of print] Impact factor 2015: 4.883;
76. Armenia D, Di Carlo D, Calcagno A, Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, Santoro MM. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. **J Antimicrob Chemother.** **2016** [Epub ahead of print] Impact factor 2016: 5.071;
77. Marinaro L, Calcagno A, Ripamonti D, Cenderello G, Pirriatore V, Trentini L, Salassa B, Bramato C, Orofino G, D'Avolio A, Rizzi M, Di Perri G, Rusconi S, Bonora S. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. **J Clin Virol.** **2016**;87:30-36. Impact factor 2015:2.647;
78. Guaraldi G, Menozzi M, Zona S, Calcagno A, Silva AR, Santoro A, Malagoli A, Dolci G, Mussi C, Mussini C, Cesari M, Khoo SH. Impact of polypharmacy on antiretroviral prescription in people living with HIV. **J Antimicrob Chemother.** **2016** [Epub ahead of print] Impact factor 2015: 5.071;
79. Calcagno A, Romito A, Atzori C, Ghisetti V, Cardellino C, Audagnotto S, Scarvaglieri E, Lipani F, Imperiale D, Di Perri G, Bonora S. Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis. **J Neuroimmune Pharmacol.** **2016** [Epub ahead of print] Impact factor 2015: 3.896;

80. Sanfilippo C, Nunnari G, Calcagno A, Malaguarnera L, Blennow K, Zetterberg H, Di Rosa M. The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). **Virus Res.** **2016**; 227:220-230. Impact factor 2015: 2.526;
81. Calcagno A, Cusato J, D'Avolio A, Bonora S. Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. **Clin Pharmacokinet.** **2016** [Epub ahead of print] Impact factor 2015: 4.829;
82. Gili S, Mancone M, Ballocca F, Grosso Marra W, Calcagno A, D'Ettorre G, Cannillo M, D'Ascenzo F, Orofino G, Marruncheddu L, Lonni E, Cinque A, Vullo F, Ceccarelli G, Vilardi I, Sardella G, Vullo V, Moretti C, Fedele F, Bonora S, Gaita F. Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study. **J Cardiovasc Med (Hagerstown).** **2016** [Epub ahead of print] Impact factor 2015: 1.658;
83. Ruggiero T, Burdino E, Calcagno A, Bonora S, Boglione L, Di Perri G, Ghisetti V. HCV NS3 naturally occurring variants in HIV/HCV coinfecting DAA-naïve patients: consideration for HCV genotyping resistance testing. **Infection.** **2016** [Epub ahead of print] Impact factor 2015: 2.294;
84. d'Arminio Monforte A, Cozzi-Lepri A, Maggiolo F, Rizzardini G, Manconi PE, Gianotti N, Quirino T, Pinnetti C, Rusconi S, De Luca A, Antinori A; Iona Foundation Study cohort. Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Iona Foundation Cohort. **PLoS One.** **2016**;11(6):e0156360. Impact factor 2015: 3.54
85. Focà E, Nunnari G, Calcagno, A. The good, the bad and the ugly: Determinants of antiretroviral-associated toxicities. **Future Virology** **2016**; 11(4):239-243. Impact factor 2014: 1.011.
86. Patti F, Calcagno A, Simiele M, Bonasso M, Di Perri G, D'Avolio A, Bonora S. Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. **Am J Health Syst Pharm.** **2016**;73(11):750-4. Impact factor 2014: 1.882.
87. Calcagno A, Di Perri G, Bonora S. What do we know about tailoring treatment with tenofovir? **Pharmacogenomics.** **2016** Apr 4. [Epub ahead of print]. Impact factor 2014: 3.218.
88. Calcagno A, Simiele M, Motta I, Mornese Pinna S, Bertucci R, D'Avolio A, Di Perri G, Bonora S. Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. **AIDS Res Hum Retroviruses.** **2016** [Epub ahead of print]. Impact factor 2014: 2.325.
89. Ballocca F, Gili S, D'Ascenzo F, Marra WG, Cannillo M, Calcagno A, Bonora S, Flammer A, Coppola J, Moretti C, Gaita F. HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. **Prog Cardiovasc Dis.** **2016** [Epub ahead of print] Impact factor 2014: 2.418.
90. Trentalange A, Calcagno A, Ghisetti V, Atzori C, Busolli P, Bonora S, Imperiale D. Clearance of cerebrospinal fluid JCV DNA with mirtazapine in a patient with progressive multifocal leukoencephalopathy and sarcoidosis. **Antivir Ther.** **2016.** [Epub ahead of print]. Impact factor 2014: 3.020.
91. Gili S, Grosso Marra W, D'Ascenzo F, Lonni E, Calcagno A, Cannillo M, Ballocca F, Cerrato E, Pianelli M, Barbero U, Mancone M, DiNicolantonio JJ, Lavie CJ, Omedè P, Montefusco A, Bonora S, Gasparini M, Biondi-Zoccai G, Moretti C,

- Gaita F. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. **Eur Heart J.** **2016**. [Epub ahead of print]. Impact factor 2014: 15.203.
92. Lucchini A, Lipani F, Costa C, Scarvaglieri M, Balbiano R, Carosella S, Calcagno A, Audagnotto S, Barbui AM, Brossa S, Ghisetti V, Dal Conte I, Caramello P, Di Perri G. Louseborne Relapsing Fever among East African Refugees, Italy, 2015. **Emerg Infect Dis.** **2016**;22(2):298-301. Impact factor 2014: 6.750.
 93. Cusato J, Tomasello C, Simiele M, Calcagno A, Bonora S, Marinaro L, Leggieri A, Allegra S, Di Perri G, D'Avolio A. Efavirenz pharmacogenetics in a cohort of Italian patients. **Int J Antimicrob Agents.** **2015**. [Epub ahead of print] Impact factor 2014: 4.296.
 94. Motta I, Calcagno A, Baietto L, D'Avolio A, De Rosa FG, Bonora S. A probable drug-to-drug interaction between voriconazole and haloperidol in a slow CYP2C9 metabolizer. **Infez Med.** **2015**;23(4):367-9. Not impacted.
 95. Bonora S, Calcagno A, Trentalange A, Perri GD. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. **Expert Opin Pharmacother.** **2015** Dec 5. [Epub ahead of print] Impact factor 2014: 3.534.
 96. Fatiguso G, Allegra S, Calcagno A, Baietto L, Motta I, Favata F, Cusato J, Bonora S, Perri GD, D'Avolio A. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. **Int J Pharm.** **2015** Nov 28. [Epub ahead of print] Impact factor 2014: 3.650
 97. Calcagno A., Rostagno R., Arnaudo I., Zanusso G., Bonora S., Lucchini A., Maiello A., Dal Conte I., Meoli I., Ferrari S., Monaco S., Rizzuto N., Di Perri G. CSF 14-3-3 protein and its ζ isoform are prognostic markers in HIV positive patients with CNS disease. **Infectious Diseases & Tropical Medicine** **2015**; 1 (2): e92. Not Impacted.
 98. Calcagno A, Cusato J, Marinaro L, Simiele M, Lucchiari M, Alcantarini C, Tettoni MC, Trentini L, Mengozzi G, D'Avolio A, Di Perri G, Bonora S. Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment. **AIDS.** **2016** ;30(6):915-20. Impact factor 2014: 5.554.
 99. Livelli A, Orofino GC, Calcagno A, Farenga M, Penoncelli D, Guastavigna M, Carosella S, Caramello P, Pia L. Evaluation of a Cognitive Rehabilitation Protocol in HIV Patients with Associated Neurocognitive Disorders: Efficacy and Stability Over Time. **Front Behav Neurosci.** **2015** Nov 16;9:306. eCollection 2015. Impact factor 2014: 3.300.
 100. Antinori A, Marcotullio S, Andreoni M, Ammassari A, d'Arminio Monforte A, Galli M, Girardi E, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. **New Microbiol.** **2015** Jul;38(3):299-328. Impact factor 2014: 1.784.
 101. Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A, Rusconi S, Santoro MM, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, Calcagno A, Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A. An

- update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaimProject. **New Microbiol.** **2015** Nov;38(4):443-490. Impact factor 2014: 1.784.
102. Calcagno A, Cusato J, Marinaro L, Trentini L, Alcantarini C, Mussa M, Simiele M, D'Avolio A, Di Perri G, Bonora S. Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. **Pharmacogenomics J.** **2015** Oct 6. doi: 10.1038/tpj.2015.71. [Epub ahead of print] Impact factor 2014: 4.229.
 103. Calcagno A, Montrucchio C, Capetti A, Guaraldi G, Cenderello G, Calza L, Lanzafame M, Marinaro L, Tettoni MC, Trentini L, D'Avolio A, Di Perri G, Bonora S. Raltegravir plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-positive Patients: Safety, Efficacy and Pharmacokinetics. **Curr HIV Res.** **2015** Sep 29. [Epub ahead of print]. Impact factor 2014: 1.757.
 104. Calcagno A, Trentalange A, Simiele M, Marinaro L, Patti F, Tettoni MC, Trentini L, Di Perri G, D'Avolio A, Bonora S. Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. **Ther Drug Monit.** **2015**;37(5):695-6. Impact factor 2014: 2.376.
 105. Calcagno A, Atzori C, Romito A, Vai D, Audagnotto S, Stella ML, Montrucchio C, Imperiale D, Di Perri G, Bonora S. Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. **J Neurovirol.** **2015**. [In Press] Impact factor 2014: 2.595.
 106. Siccardi M, Olagunju A, Simiele M, D'Avolio A, Calcagno A, Di Perri G, Bonora S, Owen A. Class-specific relative genetic contribution for key antiretroviral drugs. **J Antimicrob Chemother.** **2015**. [In Press] Impact factor 2014: 5.313.
 107. Bonora S, Rusconi S, Calcagno A, Bracchi M, Viganò O, Cusato J, Lanzafame M, Trentalange A, Marinaro L, Siccardi M, D'Avolio A, Galli M, Di Perri G. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). **J Antimicrob Chemother.** **2015** [In Press] Impact factor 2014: 5.313.
 108. Calcagno A, Motta I, Ghisetti V, Lo Re S, Alice T, Marinaro L, Milia MG, Tettoni MC, Trentini L, Orofino G, Salassa B, Di Perri G, Bonora S. HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients. **AIDS Res Hum Retroviruses.** **2015** [In Press] Impact factor 2014: 2.325.
 109. Calcagno A, D'Avolio A, Bonora S. Pharmacokinetic and pharmacodynamic evaluation of Raltegravir and Experience from Clinical Trials in HIV-positive Patients. **Expert Opinion On Drug Metabolism and Toxicology** **2015**; 11(7):1167-76. Impact factor 2013: 2.934.
 110. Baietto L, Calcagno A, Motta I, Baruffi K, Poretti V, Di Perri G, Bonora S, D'Avolio A. A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. **J Antimicrob Chemother.** **2015** [In Press] Impact factor 2014: 5.313.
 111. Simiele M, Carcieri C, De Nicolò A, Ariaudo A, Sciandra M, Calcagno A, Bonora S, Di Perri G, D'Avolio A. A LC-MS method to quantify tenofovir urinary concentrations in treated patients. **J Pharm Biomed Anal.** **2015**;114:8-11. Impact factor 2013: 2.829.
 112. Calcagno A, Nozza S, Muss C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Ripamonti D, Riva A, Di Perri G. Ageing with HIV:

- amultidisciplinary review. *Infection*. 2015 May 19. [Epub ahead of print] Impact factor 2013: 2.864.
113. Cerrato E, Calcagno A, D'Ascenzo F, Biondi-Zoccai G, Mancone M, Grosso Marra W, Demarie D, Omedè P, Abbate A, Bonora S, DiNicolantonio JJ, Estrada V, Escaned J, Moretti C, Gaita F. Cardiovascular disease in HIV patients: from bench to bedside and backwards. **Open Heart**. **2015**;2(1):e000174. Not Impacted.
 114. D'Ascenzo F, Cerrato E, Calcagno A, Grossomarra W, Ballocca F, Omedè P, Montefusco A, Veglia S, Barbero U, Gili S, Cannillo M, Pianelli M, Mistretta E, Raviola A, Salera D, Garabello D, Mancone M, Estrada V, Escaned J, De Marie D, Abbate A, Bonora S, Zoccai GB, Moretti C, Gaita F. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis. **Atherosclerosis** **2015**;240(1):197-204[Epub ahead of print] Impact factor 2013: 3.971.
 115. Ghisetti V, Calcagno A, Burdino E, Orofino G, Bonora S. Acute HIV infection: Improved algorithms for HIV testing. **J Clin Virol** **2015**;63:51-2. Impact factor 2013: 3.466.
 116. Calcagno A, Motta I, Milia M, Rostagno R, Simiele M, Libanore V, Fontana S, D'Avolio A, Ghisetti V, Di Perri G, Bonora S. Dried Plasma/Blood Spots for Monitoring Antiretroviral Treatment Efficacy and Pharmacokinetics: a Cross-sectional Study in Rural Burundi. **Br J Clin Pharmacol** **2015**; 79(5):801-8 Impact factor 2013: 3.688.
 117. Calcagno A, Simiele M, Alberione MC, Bracchi M, Marinaro L, Ecclesia S, Di Perri G, D'Avolio A and Bonora S. Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. **Clin Infect Dis** **2015**;60(2):311-7. Impact factor 2013: 9.416.
 118. Baietto L, D'Avolio A, Cusato J, Pace S, Calcagno A, Motta I, Corcione S, Di Perri G, De Rosa FG. Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. **J Antimicrob Chemother**. **2014**;70(1):307-8. Impact factor 2014: 5.313.
 119. Calcagno A, Di Perri G, Bonora S. Pharmacokinetics and Pharmacodynamics of Antiretrovirals in the Central Nervous System. **Clinical Pharmacokinetics** **2014**. 2014;53(10):891-906. Impact factor 2013: 5.486;
 120. Trentalange A, Calcagno A, Raviolo S, Prochet A, Audagnotto S, Ghisetti V, Di Perri G and Bonora S. Cytomegalovirus Central Nervous System Compartmentalization in a Patient Presenting with AIDS. **Antiviral therapy** **2014**. [Epub ahead of print] Impact factor 2013: 3.143;
 121. Bonora S, Calcagno A, Viganò O, Bigliano P, Marinaro L, Colella E, Orofino G, Trentini L, Tettoni MC, D'Avolio A, Mercadante S, Galli M, Di Perri G and Rusconi S. Efficacy, Tolerability and Virological Consequences of Long-term Use of Unboosted Atazanavir plus 2 NRTIs in HIV-infected Patients. **Current HIV Research** **2014**;12(5):339-46. Impact factor 2013: 2.135;
 122. Calcagno A, Baietto L, Pagani N, Simiele M, Audagnotto S, D'Avolio A, De Rosa FG, Di Perri G and Bonora S. Voriconazole and Atazanavir: a CYP 2C19-dependant Manageable Drug to Drug Interaction. **Pharmacogenomics** **2014**;15(10):1281-6. Impact factor 2013: 3.425;
 123. Cannillo M, D'Ascenzo F, Grosso Marra W, Cerrato E, Calcagno A, Omedè P, Bonora S, Mancone M, Vizza D, DiNicolantonio JJ, Pianelli M, Barbero U, Gili

- S, Annone U, Raviola A, Salera D, Mistretta E, Vilardi I, Colaci C, Abbate A, Zoccai GB, Moretti C, Gaita F. Heart failure in patients with human immunodeficiency virus: a review of the literature. **J Cardiovasc Med (Hagerstown)** **2014**;16(5):383-9. Impact factor 2012:1.407
124. Lanzafame M, Bonora S, Lattuada E, Calcagno A, Di Perri G, Concia E. Disappearance of renal stones in a HIV-1-infected patient after reduction of atazanavir dose. **AIDS Res Hum Retroviruses** **2014**;30(9):835-6. Impact factor 2013:2.57
125. D'Avolio A, Carcieri C, Cusato J, Simiele M, Calcagno A, Allegra S, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. **J Antimicrob Chemother.** **2014**. [Epub ahead of print] Impact factor 2014: 5.313.
126. D'Ascenzo F, Quadri G, Cerrato E, Calcagno A, Omedè P, Grosso Marra W, Abbate A, Bonora S, Biondi Zoccai G, Moretti C, Gaita F. A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era. **J Cardiovasc Med (Hagerstown).** **2014**. [Epub ahead of print] Impact factor 2013:1.407;
127. Calcagno A, Alberione MC, Romito A, Imperiale D, Ghisetti V, Audagnotto S, Lipani F, Raviolo S, Di Perri G, Bonora S. Prevalence and predictors of blood-brain barrier damage in the HAART era. **J Neurovirol.** **2014**;20(5):521-5. Impact factor 2014:2.595.
128. D'Ascenzo F, Cerrato E, Appleton D, Moretti C, Calcagno C, Abouzaki N, Vetrovec G, Lhermusier T, Carrie D, Das Neves B, Escaned J, Cassese S, Kastrati A, Chinaglia A, Belli R, Capodanno D, Tamburino C, Santilli F, Parodi G, Vachiat A, Manga P, Vignali L, Mancone M, Sardella G, Fedele F, Di Nicolantonio JJ, Omedè P, Bonora S, Gaita F, Abbate A, Biondi Zoccai G. Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients With Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. **Thrombosis Research.** **2014**;134(3):558-64. Impact factor 2013:2.427.
129. Calcagno A, Marinaro L, Nozza S, Aldieri C, Carbone A, Ghisetti V, Trentalange A, D'Avolio A, Castagna A, Di Perri G and Bonora S. Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. **Antiviral Res.** **2014**.108: 44-7 Impact factor 2013: 3.434.
130. Calcagno A, Lamorde M, D'Avolio A and Bonora S. Personalizing HIV Therapeutics in Resource-Limited Rural Communities: Lessons Learned From the Use of New Tools in Africa. **Current Pharmacogenomics and Personalized Medicine.** **2014**;12(1):1-14 Not Impacted
131. De Nicolò A, Simiele M, Calcagno A, Abdi AM, Bonora S, Di Perri G and D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens. **Antimicrob Agents Chemother.** **2014**;58(7):4042-7. Impact factor 2012: 4.565.
132. Calcagno A, Nozza S, Simiele M, Milia MG, Chiappetta S, D'Avolio A, Ghisetti V, Lazzarin A, Di Perri G, Bonora S. Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. **J Antimicrob Chemother.** **2014**;69(9):2586-8. Impact factor 2013: 5.313.

133. De Nicolò A, Simiele M, Calcagno A, Mohamed Abdi A, Bonora S, Di Perri G, D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens. **Antimicrob Agents Chemother.** **2014.** 58(7): 4042-7. Impact factor 2013:4.451.
134. Corcione S, Cardellino CS, Calcagno A, Fossati L, Costa C, Cavallo R, Di Perri G, De Rosa FG. Health-care Associated KPC-BSI: The Time Has Come. **Clin Infect Dis.** **2014.** 59(2);321-2. Impact factor 2013: 9.416;
135. Salizzoni S, D'Ascenzo F, Moretti C, Bonora S, Calcagno A, Omedè P, Montrucchio C, Cerrato E, Colaci C, Sheiban I, Marra S, Rinaldi M, Gaita F Transcatheter aortic valve implantation in a 54-year-old patient with aggressive HIV. **World J Clin Cases.** **2014;**2(4):97-9. Not Impacted
136. Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, Monforte Ad; Icona Foundation Study Group. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. **BMC Infect Dis.** **2014;**14(1):79. Impact factor 2013: 2.561.
137. Nozza S, Bigoloni A, Calcagno A, Galli L, Pignataro AR, D'Avolio A, Carbone A, Ripa M, Bonora S, Lazzarin A, Castagna A. Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. **J Antimicrob Chemother.** **2014** 69(5);1436-9. Impact factor 2013: 5.313.
138. De Francia S, D'Avolio A, Ariaudo A, Pirro E, Piccione F, Simiele M, Fava C, Calcagno A, Di Perri G, Saglio G. Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia. **Ther Drug Monit.** **2014;** 36(3):410-2. Impact factor 2013: 1.926.
139. Calcagno A, D'Avolio A, Di Perri G and Bonora S. Comment on "Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral therapy is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid". **J Acquir Immune Defic Syndr.** 2013; 62(4):e118-9. Impact factor 2013: 4.394.
140. Calcagno A, Cusato J, Simiele M, et al. High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. **J Antimicrob Chemother.** **2014;** 69(1): 241-5. Impact factor 2013: 5.313.
141. Ruggiero T, De Rosa F, Cerutti F, Pagani N, Alice T, Stella ML, Milia MG, Calcagno A, Burdino E, Gregori G, Urbino R, Di Perri G, Ranieri MV, Ghisetti V. A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection. **Influenza Other Respi Viruses.** 2013; 7(6):1416-26. Impact factor 2013:1.895;
142. Calcagno A, Baietto L, Pagani N, et al. Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. **Scand J Infect Dis.** 2013; 45(11):882-884. Impact factor 2013: 1.640
143. D'Avolio A, Cusato J, Calcagno A and Di Perri G. Estimating Ribavirin plasma exposure: genetics or therapeutic drug monitoring? **J Hepatol.** 2013; 59 (3):633-4. Impact factor 2013:10.401
144. Calcagno A, Trentini L, Marinaro L, Montrucchio C, D'Avolio A, Ghisetti V, Di Perri G, Bonora S. Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART

- in late pregnancy. *J Antimicrob Chemother.* 2013; 68(8): 1938-9. Impact factor 2013: 5.439;
145. Calcagno A, Nozza S, de Requena DG, Galli A, D'Avolio A, Simiele M, Chiappetta S, Di Perri G, Lazzarin A, Bonora S. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. *J Antimicrob Chemother.* 2013; 68(7): 1686-8. Impact factor 2013: 5.439;
146. Calcagno A, Boglione L, De Rosa FG, Di Perri G, Bonora S. Elimination Half-Life May Explain the Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1. *Clin Infect Dis.* 2013; 56(11):1677-8. Impact factor 2013: 9.416
147. Calcagno A, Gonzalez de Requena D, Simiele M, D'Avolio A, Tettoni M, Salassa B, Orofino G, Bramato C, Libanore V, Motta I, Bigliano P, Orsucci E, Di Perri G, Bonora S. Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. *Antimicrob Agents Chemother.* 2013; 57(4):1840-3. Impact factor 2013: 4.451
148. Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastrì E, Buonomini A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF. Impact of pre-therapy viral load on virological response to modern first-line HAART. *Antivir Ther.* 2013; 18(7): 867-876. Impact factor 2013: 3.143
149. Cerrato E, D'Ascenzo F, Biondi-Zoccai G, Calcagno A, Frea S, Grosso Marra W, Castagno D, Omedè P, Quadri G, Sciuto F, Presutti D, Frati G, Bonora S, Moretti C, Gaita F. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. *Eur Heart J.* 2013; 34(19): 1432-6. Impact factor 2013: 14.723.
150. Calcagno A, Tettoni MC, Simiele M, Trentini L, Montrucchio C, D'Avolio A, Di Perri G, Bonora S. Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. ***J Antimicrob Chemother* 2013.** 68(2): 482-4. Impact factor 2013: 5.439;
151. Rekić D, Röshammar D, Bergstrand M, Tarning J, Calcagno A, D'Avolio A, Ormaasen V, Vigan M, Barrail-Tran A, Ashton M, Gisslén M, Abelö A. External Validation of the Bilirubin-Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. ***AAPS J.* 2013;** 15(2): 308-15. Impact factor 2012: 4.386;
152. D'Avolio A, Simiele M, Calcagno A, Siccardi M, Larovere G, Agati S, Baietto L, Cusato J, Tettoni M, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. *J Antimicrob Chemother.* 2012; 68(4): 907-10. Impact factor 2012: 5.338;
153. D'Avolio A, Ciancio A, Siccardi M, Smedile A, Simiele M, Cusato J, Baietto L, Marucco DA, Cariti G, Calcagno A, Gonzalez de Requena D, Sciandra M, Troshina G, Caviglia GP, Bonora S, Rizzetto M, Di Perri G. Negative Predictive

- Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. *Ther Drug Monit* 2012; 34(6):722-8. Impact factor 2012: 2.234;
154. Calcagno A, Rostagno R, Di Perri G. Anti-CD20 antibody therapy for B-cell lymphomas. *N Engl J Med*. 2012;367(9):877-8. Impact factor 2012: 51.658;
155. Bibas M, Lorenzini P, Cozzi-Lepri A, Calcagno A, di Giambenedetto S, Costantini A, Castagna A, Manfrin V, Monforte AD, Antinori A; for the ICONA Cohort Study Group. Polyclonal serum free light chains elevation in HIV-infected patients. *AIDS*. 2012; 26(16):2107-10. Impact factor 2012: 6.407;
156. Calcagno A, Yilmaz A, Cusato J, Simiele M, Bertucci R, Siccardi M, Marinaro L, D'Avolio A, Di Perri G, Bonora S. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. *AIDS*. 2012;26(12):1529-33. Impact factor 2012: 6.407;
157. D'Avolio A, De Nicolò A, Simiele M, Turini S, Agnesod D, Boglione L, Cusato J, Baietto L, Cariti G, Calcagno A, Sciandra M, Di Perri G, Bonora S. Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. *J Pharm Biomed Anal*. 2012;66:376-80. Impact factor 2012: 2.947;
158. Calcagno A, D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Baietto L, Siccardi M, Bonora S and Di Perri G. Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spots Devices. *British Journal of Clinical Pharmacology* 2012;74(1):134-40. Impact factor 2012: 3.578;
159. D'Avolio A, Ciancio A, Siccardi M, Smedile A, Baietto L, Simiele M, Aguilar Marucco D, Cariti G, Calcagno A, Gonzalez de Requena D, Sciandra M, Cusato J, Troshina M, Bonora S, Rizzetto M and Di Perri G. ITPA polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associated anaemia in patients under standard anti-HCV treatment *Therapeutic Drug Monitoring* 2012;34(2):165-70. Impact factor 2012: 2.234;
160. Bonora S, Calcagno A, Cometto C, Fontana S, Aguilar D, D'Avolio A, Gonzalez de Requena D, Maiello A, Dal Conte I, Lucchini A and Di Perri G. Short Term Additional Enfuvirtide Therapy is Associated with a Greater Immunological Recovery in HIV Very Late Presenters: a Controlled Pilot Study. *Infection* 2012;40(1):69-75. Impact factor 2012: 2.440;
161. Siccardi M, D'Avolio A, Rodriguez-Novoa S, Simiele M, Baietto L, Calcagno A, Moss D, Back D, Owen A, Bonora S and Di Perri G. Intra and inter patient pharmacokinetic variability of raltegravir in the clinical setting. *Therapeutic Drug Monitoring* 2012;34(2):232-5. Impact factor 2012: 2.234.
162. D'Avolio, Ciancio A, Siccardi M, Baietto L, Simiele M, Cariti G, Calcagno A, Smedile A, Cusato J, Bonora S, Rizzetto M and Di Perri G. Ribavirin Pharmacokinetics and IL28 plus CYP27B1 SNPs as predictors of response to Peg-IFN/RBV treatment in HCV $\frac{1}{4}$ infected patients. *Hepatology* 2011; 54(6):2278-9. Impact factor 2011: 11.665;
163. Calcagno A, Bonora S, Simiele M, Rostagno R, Tettoni MC, Bonasso M, Romito A, Imperiale D, D'Avolio A and Di Perri G. Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. *AIDS* 2011; 25(11):1437-9. Impact factor 2011: 6.245;

164. Calcagno A, Nozza S, Bonora S, Castagna A, Gonzalez de Requena D, D'Avolio A, Lazzarin A and Di Perri G. Pharmacokinetics of the Raltegravir/Maraviroc/Etravirine Combination. *J Antimicrob Chemother* 2011; 66(8):1932-4. Impact factor 2011: 5.068;
165. Bonora S, Gonzalez de Requena D, D'Avolio A, Calcagno A, Tettoni MC, Siccardi M, Baietto L, Simiele M, Trentini L, Di Perri G. Pharmacokinetics of switching unboosted Atazanavir co-administered with Tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. *Antiviral Therapy* 2011; 16(4): 499-504. Impact factor 2011: 3.161;
166. Gonzalez de Requena D, Bonora S, Viganò O, Calcagno A, Cometto C, D'Avolio A, Baietto L, Ghisetti V, Magnani S, Ferramosca S, Vitiello P, Galli M, Rusconi S, Di Perri G. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. *J Antimicrob Chemother* 2011; 66(1): 192-200. Impact factor 2011: 5.068;
167. Calcagno A, Baietto L, De Rosa FG, Tettoni MC, Libanore V, Bertucci R, D'Avolio A, Di Perri G. Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. *J Antimicrob Chemother* 2011; 66(1):224-5 Impact factor 2011: 5.068;
168. Lanzafame M, Bonora S, Lattuada E, Calcagno A, Vento S. A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients. *Braz J Infect Dis.* 2011; 15(5):498-500. Impact factor 2011: 1.005;
169. Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan W, Castagna A, Lazzarin A, Calcagno A, Bonora S, Back D, Di Perri G, Owen A. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521C>T polymorphism. *Pharmacogenet Genomics.* 2010; 20(12):759-65. Impact factor 2010: 3.865;
170. Calcagno A, Rostagno R, Audagnotto S, D'Avolio A, Bonora S, Ghisetti V, Di Perri G. Is peritoneal fluid a sanctuary site for HIV? *J Antimicrob Chemother* 2010; 65(9):2052-3. Impact factor 2010: 4.659;
171. Calcagno A, Bonora S, D'Avolio A, Siccardi M, Simiele M, Chiesa M, Gonzalez de Requena D, Di Perri G. Raltegravir penetration in seminal plasma of healthy volunteers. *Antimicrob Agents Chemother* 2010; 54(6):2744-5. Impact factor 2010: 4.672;
172. Calcagno A, Bonora S, Bertucci R, Lucchini A, D'Avolio A, Di Perri G. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. *AIDS* 2010; 24(6):931-2. Impact factor 2010: 6.348;
173. Lanzafame M, Hill A, Lattuada E, Calcagno A, Bonora S. Raltegravir: is a 400 mg once-daily dose enough? *J Antimicrob Chemother* 2010; 65(3):595-7. Impact factor 2010: 4.659;
174. Calcagno A, Bonora S, Tettoni MC, D'Avolio A, Lanzafame M, Penco G, Di Perri G. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. *J Acquir Immune Defic Syndr.* 2009; 52(3):431-2. Impact factor 2009: 4.207;
175. Bonora S, Calcagno A, Di Perri G. HIV infection: treatment of naïve patients. *Infez Med.* 2009; 17(2):69-81. Not Impacted.
176. Bonora S, Nicastrì E, Calcagno A, Gonzalez de Requena D, D'Ettoire G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. Ultrasensitive assessment of residual

- HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. *J Med Virol.* 2009; 81(3):400-5. Impact factor 2009:2.470;
177. Bonora S, Mondo A, Trentini L, Calcagno A, Lucchini A, Di Perri G. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. *Journal of Infection* 2008; 57: 78- 81. Impact factor 2008: 3.089;
178. González de Requena D, Bonora S, Castagna A, Hasson H, Marucco Aguilar D, D'Avolio A, Sciandra M, Trentini L, Calcagno A, Lazzarin A, Di Perri G. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. *J Antimicrob Chemother.* 2008;62(2):384-7. Impact factor 2008: 4.328;
179. González de Requena DG, Bonora S, Calcagno A, D'Avolio A, Siccardi M, Fontana S, Milia MG, Sciandra M, Garazzino S, Di Garbo A, Baietto L, Trentini L, Di Perri G. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. *Antimicrob Agents Chemother.* 2008; 52(3):1066-71. Impact factor 2008: 4.716;
180. Bonora S, Calcagno A, Fontana S, D'Avolio A, Siccardi M, Gobbi F, Di Perri G. Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. *Clin Infect Dis.* 2007; 45(12):1654-5. Impact factor 2007: 6.750;
181. Aguilar Marucco D, Veronese L, de Requena DG, Bonora S, Calcagno A, Cavecchia I, Sinicco A, De Rosa FG, Cariti G, Di Perri G. Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. *J Antimicrob Chemother* 2007; 59: 565- 568. Impact factor 2006: 4.038.
182. González de Requena D, Calcagno A, Bonora S, Ladetto L, D'Avolio A, Sciandra M, Siccardi M, Bargiacchi O, Sinicco A, Di Perri G. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. *AIDS.* 2006; 20(15):1977-9. Impact factor 2006: 5.632;
183. Garazzino S, Tettoni M, Calcagno A, D'Avolio A, Bonora S, Di Perri G. Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases. *J Antimicrob Chemother* 2006;58: 483- 485. Impact factor 2006: 3.891;
184. Bonora S, Calcagno A, Gonzalez de Requena D, Bargiacchi O, Di Perri G. Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors. *Infez Med* 2006; 14: 61-70.

Total Impact Factor: 719.070
Published articles: 185 (172 with Impact Factor)
Average Impact Factor: 4.180
Citations: 1909; Average Citations: 10.3
H-index (Scopus): 24
H-index (Google Scholar): 29
i10-index (Google Scholar): 87

**Lectures at
National and
International
Conferences**

- Calcagno A. “COVID-19 from a recovered healthcare worker’s perspective” – COVID-19 – A IAS Virtual Conference – July 10-11 2020.
- Calcagno A and Cavassini M. “HIV-associated neurocognitive disorders and neurological complications – An update” – 17th European AIDS Conference – November 6-9 2019, Basel, Switzerland.
- Calcagno A. “Antiretrovirals distribution in sanctuaries” – 11th Italian Conference on AIDS and Antiviral Research – June 5-7, 2019, Milan, Italy.
- Calcagno A. “Last Advances in HIV Pharmacogenomics” - 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, 22 - 24 May 2018, Baltimore, Maryland, USA
- Calcagno A, et al. “Age, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals’ Concentrations” - 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, 22 - 24 May 2018, Baltimore, Maryland, USA
- Calcagno A, et al. “SLC22A2 Genetic Variants and Dolutegravir Trough Concentrations Correlate with Specific Psychiatric Symptoms in HIV-positive Patients on Dolutegravir” - 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, 22 - 24 May 2018, Baltimore, Maryland, USA
- Calcagno A. “La gestione dell’HIV nella popolazione che invecchia” - XVI Congresso Nazionale SIMIT – Salerno 15-18 Ottobre 2017
- Calcagno A. “Asymptomatic CSF Escape” - Seventh International Meeting on HIV Infection of the Central Nervous System – Pollenzo – 12-14th October, 2017
- Calcagno A. “Pharmacokinetic correlates of effective HAART”- 8th Italian Conference on AIDS and Retroviruses, 2016, 6-8 June, Milano, Italy.
- Calcagno A. “Therapeutics of the CNS With HIV Infection”. Conference on Retroviruses and Opportunistic Infections. Boston, MA, US. February 22-25, 2016.
- Calcagno A. “Toxicities in HIV”. 15th European AIDS Conference. October 20th-24th 2015. Barcelona, Spain.
- Calcagno A, et al. “The relevance of CSF PK in managing CNS ART effectiveness”. Sixth International meeting on HIV infection of the Central Nervous System. October 8th-10th 2015, Matera, Italy
- Calcagno A, et al. “Antiretroviral Drug Concentrations in the Central Nervous System: Scarce, Enough or Too Much?”. 7th Italian Conference on AIDS and Retroviruses, 2015, 17-19 May, Riccione, Italy.
- Calcagno A, et al. “Blood Brain Barrier Impairment is Associated with Cerebrospinal Fluid Markers of Neuronal Damage in HIV-positive Patients”7th Italian Conference on AIDS and Retroviruses, 2015, 17-19 May, Riccione, Italy.
- Calcagno A, et al. “Concordance Among Cardiovascular Risk Scores in HIV-positive Patients: Framingham, D:A:D and Progetto Cuore”. 6th Italian Conference on AIDS and Retroviruses, 2014, 25-27 May, Roma, Italy.

- Calcagno A, et al. "Level of HIV Viremia Below 50 copies/ml Predicts Virologic Rebound in HAART-treated Patients". 14th Conference of the European AIDS Clinical Society, Bruxelles, Belgium. 16-19 October, 2013.
- Calcagno A, et al. "High Incidence of Cytomegalovirus Reactivation in HIV-positive Patients Treated for Haematological Malignancies". 5th Italian Conference on AIDS and Retroviruses, 2013, 12-14 May, Torino, Italy.
- Calcagno A, et al. "Cerebrospinal Fluid Concentrations Above Drugs IC95s are Associated With CSF Viral Loads Below 50 copies/ml". 14th International Workshop on Clinical Pharmacology of HIV Treatment, Amsterdam, Netherlands, 22-24 April 2013.
- Calcagno A, et al. "Measurement of CSF tau, phosphorylated tau and β -amyloid (1-42) in HIV-positive patients at different stages of infection." 4th Italian Conference on AIDS and Retroviruses, 2012, Naples, Italy.
- Calcagno A "TB, poly-pharmacy and Drug Interactions". EACS Pre-Educational Course, 13th European AIDS Conference, October 12-15, 2011 - Belgrade, Serbia
- Calcagno A, et al. "Monitoring of Virological and Pharmacological Cerebrospinal Fluid Parameters in HAART-treated HIV-positive Patients in the Clinical Setting". ICAR 2011, Florence, Italy.
- Calcagno A, et al. "A Filter-based Cross-sectional Analysis of a HIV Positive HAART-treated Cohort in Rural Burundi: Pharmacokinetics, Pharmacogenetics and Viral Load". HIV10, 10th International Congress on Drug Therapy in HIV Infection, Glasgow, Glasgow, Regno Unito, November 2010.
- Calcagno A, et al. "Raltegravir in the CSF: is Cmax more appropriate than Ctough?". 3rd Meeting on HIV Infection and the Central Nervous System, Stresa, Italy, October 2009.
- Calcagno A, et al. "La Rinascita degli Inibitori Non Nucleosidici". Convegno Nazionale SIMIT, Società Italiana di Malattie Infettive, Modena, Italia, Novembre 2009.
- Calcagno A, et al. "Greater immunological recovery associated with additional enfuvirtide in the treatment of naïve HIV-infected patients at very advanced disease stages: results of a randomized, controlled, pilot study". 1st Italian Conference on AIDS and Retroviruses, 2009, Milano, Italy.
- Calcagno A, et al. "Effect of Darunavir (DRV) genotypic inhibitory quotient (glQ) on the virological response to DRV-containing salvage regimens at 24 weeks". IWCPHT, 9th International Workshop on Clinical Pharmacology of HIV Treatment, New Orleans, USA, 2008.

Books

Co-Wrote the chapter "Aging with HIV and Oxidative stress", in the book "HIV/AIDS, Oxidative Stress and Dietary Antioxidants" Elsevier. Editors: Victor Preedy Ronald Watson. ISBN: 9780128098530.

Wrote the chapter "Antiretroviral Drug Penetration into the CNS Compartment" in the printed and online "Encyclopedia of AIDS" Springer. Editors: Thomas J. Hope, Mario Stevenson, Douglas Richman. ISBN: 978-1-4614-9610-6 (Online)

Partecipated in the writing of the chapter “Natural History of HIV Infection and Evoluton of Antiretroviral Therapy” in the book “Cardiovascular Disease in AIDS”, Springer-verlag Italia S.r.l., 2008, Barbaro G, Boccara F and Skolnik PR.

Partecipated in the writing of the chapter “Donovanosis” in the book “Infezioni Genitali: Aspetti patogenetici, clinici e diagnostici”, Latino MA, Magliano E, AMCLI, Milano, 2009.

Torino, Italy; March 25th 2021

CALCAGNO ANDREA


